Tesamorelin side effects: what the studies found
Real adverse event rates, clinical trial discontinuation numbers, and documented safety warnings from peer-reviewed literature.
This page has not yet been reviewed by a credentialed medical professional. It is educational and is not medical advice.
Safety summary: Tesamorelin
- Evidence level FDA-approved
- FDA approvedYes
- Trial discontinuationApproximately 9.6% of patients discontinued due to adverse events in pivotal Phase 3 trials vs 6.8% on placebo.
- WADA sport statusProhibited
In short: Adverse events in clinical trials include injection site reactions (erythema, pruritus, or pain in ~17%), arthralgias (13%), peripheral edema (6%), and myalgias, primarily resulting from fluid shifts associated with elevated GH and IGF-1. Because GH has anti-insulin effects, glucose tolerance must be monitored; small increases in fasting glucose and HbA1c have been observed. Because GH and IGF-1 are mitogenic, tesamorelin is contraindicated in patients with active malignancy or a history of pituitary neoplasm.
FDA Prescribing Warning: Contraindicated in patients with active malignancy, disruption of the hypothalamic-pituitary axis, or pregnancy. Monitor glucose tolerance and IGF-1 levels.
Most common side effects
Reported symptoms in clinical trials and published pharmacology literature:
| Symptom | Reported rate | Clinical context & notes |
|---|---|---|
| Injection site reactions | 17% to 25% vs 14% placebo | Erythema, pruritus, pain, and localized rash. |
| Arthralgia (joint pain) | 13% vs 11% placebo | Mild to moderate joint aching related to GH-induced fluid retention. |
| Peripheral edema | 6% vs 2% placebo | Swelling of the hands, ankles, or feet from mild fluid shifts. |
| Myalgia (muscle pain) | 5% vs 2% placebo | Transient muscle aches. |
| Paresthesia & numbness | 3% to 4% | Tingling or mild numbness in the extremities. |
Serious risks and warnings
Potential adverse reactions and biological risks identified in research:
- Impaired glucose tolerance / hyperglycemia: Because growth hormone stimulates hepatic gluconeogenesis and reduces insulin sensitivity, fasting blood glucose and HbA1c may rise.
- Elevated IGF-1 levels: IGF-1 levels rise above the normal age-adjusted range in up to 47% of patients in trials; chronic supra-normal levels require monitoring.
- Risk of malignancy progression: GH and IGF-1 are potent mitogens that promote cell division. Contraindicated in active cancer or history of pituitary neoplasm.
- Hypersensitivity reactions: Severe allergic reactions including rash, urticaria, and dyspnea have been reported.
Contraindications
This compound should not be used in individuals with:
- Active malignancy
- History of pituitary tumor or surgery
- Known hypersensitivity to tesamorelin or mannitol
- Pregnancy
Common questions about Tesamorelin safety
Does tesamorelin increase the risk of diabetes?
Tesamorelin stimulates growth hormone, which has anti-insulin actions. In Phase 3 clinical trials, small increases in fasting blood glucose and HbA1c were observed. Patients with diabetes or prediabetes require careful glucose monitoring.
Does tesamorelin cause joint pain or swelling?
Yes. Growth hormone induces fluid retention in soft tissues, which can cause arthralgias (joint pain in ~13% of patients) and peripheral edema (~6%). Symptoms are usually mild to moderate and resolve with dose adjustment or cessation.
Why is tesamorelin prohibited in competitive sport?
Tesamorelin is a synthetic growth hormone secretagogue that stimulates endogenous growth hormone production. WADA prohibits all growth hormone secretagogues at all times (Category S2) because of potential performance-enhancing and anabolic effects.